NASDAQ:CORT

Corcept Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy CORT

*Your capital is at risk

$72.65

+1.45 (+2.04%)

At Close: Jun 03, 2026

Corcept Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -7.91. In total, the insiders bought 4.09M and sold 1.85M CORT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-7.91
● Buy	4.09M shares
● Sell	1.85M shares
67% Buy Activity Negligible or No Correlation
Sell Signal Low Confidence May 27, 2026 Analysis Breakdown: Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 02, 2026 Buy	Common Stock A-Award	Mokari Atabak Chief Financial Officer	C-Suite Officer	397 Value: $14.3K
Mar 02, 2026 Buy	Common Stock A-Award	Mokari Atabak Chief Financial Officer	C-Suite Officer	397 Value: $14.3K
Mar 02, 2026 Buy	Common Stock A-Award	Guyer William Chief Development Officer	Officer	498 Value: $17.9K
Mar 02, 2026 Buy	Common Stock A-Award	Lyon Joseph Douglas See Remarks	Officer	398 Value: $14.3K
Mar 02, 2026 Buy	Common Stock A-Award	Maduck Sean See Remarks	Officer	454 Value: $16.3K
Mar 02, 2026 Buy	Common Stock A-Award	Robb Gary Charles Chief Business Officer	Officer	499 Value: $17.9K
Mar 02, 2026 Buy	Common Stock A-Award	Guyer William Chief Development Officer	Officer	498 Value: $17.9K
Mar 02, 2026 Buy	Common Stock A-Award	Maduck Sean See Remarks	Officer	454 Value: $16.3K
Mar 02, 2026 Buy	Common Stock A-Award	Robb Gary Charles Chief Business Officer	Officer	499 Value: $17.9K
Feb 27, 2026 Buy	Stock Option (right to buy) A-Award	Guyer William Chief Development Officer	Officer	140 000 Value: $5.00M
Feb 27, 2026 Buy	Stock Option (right to buy) A-Award	Robb Gary Charles Chief Business Officer	Officer	140 000 Value: $5.00M
Feb 27, 2026 Buy	Stock Option (right to buy) A-Award	Hunt Hazel Chief Scientific Officer	Officer	140 000 Value: $5.00M
Feb 27, 2026 Buy	Stock Option (right to buy) A-Award	Maduck Sean See Remarks	Officer	140 000 Value: $5.00M
Feb 27, 2026 Buy	Stock Option (right to buy) A-Award	Mokari Atabak Chief Financial Officer	C-Suite Officer	140 000 Value: $5.00M
Feb 27, 2026 Buy	Stock Option (right to buy) A-Award	Belanoff Joseph K Chief Executive Officer	CEO / President	460 000 Value: $16.4M
Feb 27, 2026 Buy	Stock Option (right to buy) A-Award	Lyon Joseph Douglas See Remarks	Officer	140 000 Value: $5.00M
Feb 24, 2026 Buy	Stock option (right to buy) M-Exempt	Wilson James N Director	Director	100 000 Value: $388.0K
Feb 24, 2026 Sell	Common Stock G-Gift	Wilson James N Director	Director	89 364 Value: $0
Feb 24, 2026 Sell	Common Stock F-InKind	Wilson James N Director	Director	10 636 Value: $388.0K
Feb 24, 2026 Buy	Common Stock M-Exempt	Wilson James N Director	Director	100 000 Value: $388.0K
Feb 24, 2026 Buy	Common Stock J-Other	Wilson James N Director	Director	89 364 Value: $3.26M
Feb 09, 2026 Sell	Common Stock F-InKind	Hunt Hazel Chief Scientific Officer	Officer	77 968 Value: $3.22M
Feb 09, 2026 Buy	Common Stock M-Exempt	Hunt Hazel Chief Scientific Officer	Officer	150 000 Value: $582.0K
Feb 09, 2026 Buy	Stock Option (right to buy) M-Exempt	Hunt Hazel Chief Scientific Officer	Officer	150 000 Value: $582.0K
Feb 03, 2026 Buy	Stock option (right to buy) M-Exempt	Guyer William Chief Development Officer	Officer	20 000 Value: $433.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT CORCEPT THERAPEUTICS INCORPORATED

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have ...

Read Full Profile Here